Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALC Stock Forecast 2025-2026
$73.97
Current Price
$37.03B
Market Cap
Buy 20
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to ALC Price Targets
+66.3%
To High Target of $123.00
+28.4%
To Median Target of $95.00
+4.8%
To Low Target of $77.53
ALC Price Momentum
+0.1%
1 Week Change
-3.4%
1 Month Change
-20.1%
1 Year Change
-12.9%
Year-to-Date Change
-25.4%
From 52W High of $99.20
+3.4%
From 52W Low of $71.55
📊 TOP ANALYST CALLS
Did ALC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Alcon is one of their latest high-conviction picks.
Latest ALC Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, ALC has a bullish consensus with a median price target of $95.00 (ranging from $77.53 to $123.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $73.97, the median forecast implies a 28.4% upside. This outlook is supported by 20 Buy, 8 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by David Adlington at JP Morgan, suggesting a 4.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALC Analyst Ratings
20
Buy
8
Hold
0
Sell
ALC Price Target Range
Low
$77.53
Average
$95.00
High
$123.00
Current: $73.97
Latest ALC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 21, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $91.00 |
| Oct 13, 2025 | BTIG | Ryan Zimmerman | Buy | Maintains | $91.00 |
| Oct 13, 2025 | Barclays | Matt Miksic | Equal-Weight | Initiates | $86.00 |
| Sep 29, 2025 | Stifel | Thomas Stephan | Buy | Maintains | $85.00 |
| Aug 21, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $80.00 |
| Aug 21, 2025 | Baird | Jeff Johnson | Outperform | Maintains | $95.00 |
| Aug 21, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $110.00 |
| Aug 21, 2025 | Stifel | Tom Stephan | Buy | Maintains | $90.00 |
| Aug 21, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Aug 21, 2025 | JP Morgan | David Adlington | Neutral | Downgrade | $77.53 |
| Aug 20, 2025 | Needham | David Saxon | Buy | Reiterates | $107.00 |
| Aug 13, 2025 | Needham | David Saxon | Buy | Reiterates | $107.00 |
| Aug 6, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Reinstates | $93.00 |
| Jul 15, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $84.00 |
| May 14, 2025 | Needham | David Saxon | Buy | Reiterates | $110.00 |
| Mar 31, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $112.00 |
| Mar 28, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $120.00 |
| Mar 28, 2025 | Needham | David Saxon | Buy | Maintains | $110.00 |
| Mar 20, 2025 | Needham | David Saxon | Buy | Reiterates | $107.00 |
| Feb 27, 2025 | Needham | David Saxon | Buy | Maintains | $107.00 |
Alcon Inc. (ALC) Competitors
The following stocks are similar to Alcon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alcon Inc. (ALC) Financial Data
Alcon Inc. has a market capitalization of $37.03B with a P/E ratio of 34.2x. The company generates $10.02B in trailing twelve-month revenue with a 10.7% profit margin.
Revenue growth is +4.0% quarter-over-quarter, while maintaining an operating margin of +11.2% and return on equity of +5.0%.
Valuation Metrics
Market Cap
$37.03B
Enterprise Value
$40.44B
P/E Ratio
34.2x
PEG Ratio
-1.7x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+4.0%
Gross Margin
+53.5%
Operating Margin
+11.2%
Net Margin
+10.7%
EPS Growth
-21.1%
Financial Health
Cash/Price Ratio
+3.9%
Current Ratio
2.6x
Debt/Equity
23.8x
ROE
+5.0%
ROA
+2.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Alcon Inc. (ALC) Business Model
About Alcon Inc.
What They Do
Develops and manufactures eye care solutions.
Business Model
Alcon generates revenue through the sale of a diverse range of eye care products, including contact lenses and surgical devices. The company operates in both the medical device and pharmaceutical sectors, focusing on innovations to address various ocular conditions. Its extensive portfolio and collaborations with healthcare professionals enhance its market reach and product offerings.
Additional Information
Established in 1945, Alcon has a global presence in over 140 countries and is recognized for its commitment to innovation and clinical research. The company aims to improve visual health and quality of life for millions, maintaining a strong pipeline of products through partnerships with medical institutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
25,000
CEO
Mr. David J. Endicott
Country
Switzerland
IPO Year
N/A
Website
www.alcon.comAlcon Inc. (ALC) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
MTD posted stronger-than-expected Q3 results, lifted by segment growth and solid guidance for 2025 and 2026.
Nov 07, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Alcon has released investor materials highlighting the value of its merger proposal for STAAR stockholders.
Why It Matters
Alcon's release on the merger proposal could influence STAAR's stock price, signaling potential changes in company valuation and shareholder sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Alcon (ALC) is being evaluated for its Q3 2025 performance, with a focus on key metrics beyond traditional Wall Street estimates. Further details on metrics are awaited.
Why It Matters
Analyzing Alcon's performance metrics beyond standard estimates can reveal growth potential and risks, influencing investment decisions and market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Investors are comparing Alcon (ALC) and Intuitive Surgical, Inc. (ISRG) for potential value in the Medical - Instruments sector.
Why It Matters
The comparison between Alcon and Intuitive Surgical highlights potential investment opportunities, signaling which stock may offer better value and growth prospects in the medical instruments sector.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
4 days ago
Quick Summary
Broadwood Partners, holding 27.5% of STAAR Surgical, opposes Alcon's acquisition of STAAR and urges shareholders to vote "AGAINST" the deal using their GREEN Proxy Card.
Why It Matters
Broadwood's opposition to Alcon's acquisition of STAAR could influence STAAR's stock price and investor sentiment, impacting shareholder value and future corporate strategy.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MonotaRO was the largest detractor in the quarter, while FirstCash and Martin Marietta Materials were the top contributors.
Why It Matters
MonotaRO's decline may signal challenges in the B2B e-commerce sector, affecting investor sentiment. In contrast, strong performance from FirstCash and Martin Marietta suggests resilience in retail and materials sectors.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Yunqi Capital, a 5.1% shareholder of STAAR Surgical (NASDAQ:STAA), has addressed the Board following STAAR's decision to postpone a Special Meeting regarding its proposed sale to Alcon Inc.
Why It Matters
Yunqi Capital's influence as a significant shareholder and the postponed sale to Alcon could impact STAAR's stock price and strategic direction, affecting investor sentiment and decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ALC Stock
What is Alcon Inc.'s (ALC) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Alcon Inc. (ALC) has a median price target of $95.00. The highest price target is $123.00 and the lowest is $77.53.
Is ALC stock a good investment in 2026?
According to current analyst ratings, ALC has 20 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $73.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALC stock?
Wall Street analysts predict ALC stock could reach $95.00 in the next 12 months. This represents a 28.4% increase from the current price of $73.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alcon Inc.'s business model?
Alcon generates revenue through the sale of a diverse range of eye care products, including contact lenses and surgical devices. The company operates in both the medical device and pharmaceutical sectors, focusing on innovations to address various ocular conditions. Its extensive portfolio and collaborations with healthcare professionals enhance its market reach and product offerings.
What is the highest forecasted price for ALC Alcon Inc.?
The highest price target for ALC is $123.00 from at , which represents a 66.3% increase from the current price of $73.97.
What is the lowest forecasted price for ALC Alcon Inc.?
The lowest price target for ALC is $77.53 from David Adlington at JP Morgan, which represents a 4.8% increase from the current price of $73.97.
What is the overall ALC consensus from analysts for Alcon Inc.?
The overall analyst consensus for ALC is bullish. Out of 24 Wall Street analysts, 20 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are ALC stock price projections?
Stock price projections, including those for Alcon Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 8, 2025 6:20 AM UTC